Estrella Immunopharma, Inc. (ESLA) vs TScan Therapeutics, Inc. (TCRX)
A side-by-side comparison of Estrella Immunopharma, Inc. and TScan Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ESLA
Estrella Immunopharma, Inc.
$0.43HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TCRX
TScan Therapeutics, Inc.
$0.28HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ESLA vs TCRX
growth of $100 · dividends reinvested · last 5yESLA -95.5% (-46.2%/yr)TCRX -96.1% (-47.8%/yr)ESLA compounded faster over this window
ESLA TCRX
ESLA vs TCRX: by the numbers
- •ESLA is the larger company ($18M vs $17M market cap).
- •Both run net losses; ESLA's is the smaller (0.00% vs -1655.35% net margin).
Metrics side by side
Valuation
| Metric | ESLA | TCRX |
|---|---|---|
| P/S ratio | N/A | 2.37 |
| P/B ratio | N/A | 0.24 |
Profitability
| Metric | ESLA | TCRX |
|---|---|---|
| Gross margin | 0.00% | 72.24% |
| Operating margin | 0.00% | -1315.38% |
| Net margin | 0.00% | -1655.35% |
| ROE | N/A | -170.55% |
| ROIC | N/A | -79.20% |
Growth (annualized)
| Metric | ESLA | TCRX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 3.60% |
| Total return CAGR (5Y) | -46.34% | -48.85% |
Frequently asked
- How have ESLA and TCRX total returns compared?
- Over the past 5 years, ESLA delivered -46.34% and TCRX delivered -48.85% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.